KRAS Biomarkers
Diatech Pharmacogenetics, Merck KGaA Expand RAS Biomarker Testing Pact in Middle East, Africa
The companies are collaborating to improve access to biomarker testing to inform the use of targeted therapies in colorectal cancer across the region.
Elicio Therapeutics Carves Out Registrational Path for KRAS Cancer Vaccine
The firm said it has received positive feedback from the FDA on the design of a Phase III trial of ELI-002 in KRAS-mutant pancreatic cancer.
Amgen's Lumakras, Vectibix Net FDA Approval in KRAS G12C-Mutant Colorectal Cancer
The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.
Silexion Therapeutics Prices $5M Public Offering
The firm will use the proceeds to advance preclinical studies of its small interfering RNA therapy in KRAS-mutant colorectal and pancreatic cancer.
FDA Issues Draft Guidance on Tissue Biopsies in Clinical Trials
The agency affirmed the use of biopsies for biomarker-driven trials but cautioned against optional biopsies that offer little value to the patient or trial.